745 related articles for article (PubMed ID: 33149131)
21. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
Wang Y; Park JYP; Pacis A; Denroche RE; Jang GH; Zhang A; Cuggia A; Domecq C; Monlong J; Raitses-Gurevich M; Grant RC; Borgida A; Holter S; Stossel C; Bu S; Masoomian M; Lungu IM; Bartlett JMS; Wilson JM; Gao ZH; Riazalhosseini Y; Asselah J; Bouganim N; Cabrera T; Boucher LM; Valenti D; Biagi J; Greenwood CMT; Polak P; Foulkes WD; Golan T; O'Kane GM; Fischer SE; Knox JJ; Gallinger S; Zogopoulos G
Clin Cancer Res; 2020 Oct; 26(20):5462-5476. PubMed ID: 32816949
[TBL] [Abstract][Full Text] [Related]
22. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
[TBL] [Abstract][Full Text] [Related]
24. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
[TBL] [Abstract][Full Text] [Related]
25. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
[TBL] [Abstract][Full Text] [Related]
26. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
Mutter RW; Riaz N; Ng CK; Delsite R; Piscuoglio S; Edelweiss M; Martelotto LG; Sakr RA; King TA; Giri DD; Drobnjak M; Brogi E; Bindra R; Bernheim G; Lim RS; Blecua P; Desrichard A; Higginson D; Towers R; Jiang R; Lee W; Weigelt B; Reis-Filho JS; Powell SN
J Pathol; 2017 Jun; 242(2):165-177. PubMed ID: 28299801
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of PALB2-associated breast cancers.
Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
[TBL] [Abstract][Full Text] [Related]
29. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
30. Whence High-Grade Serous Ovarian Cancer.
Kohn EC; Ivy SP
Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
[TBL] [Abstract][Full Text] [Related]
31. Copy number alteration features in pan-cancer homologous recombination deficiency prediction and biology.
Yao H; Li H; Wang J; Wu T; Ning W; Diao K; Wu C; Wang G; Tao Z; Zhao X; Chen J; Sun X; Liu XS
Commun Biol; 2023 May; 6(1):527. PubMed ID: 37193789
[TBL] [Abstract][Full Text] [Related]
32. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
33. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
34. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Börcsök J; Diossy M; Sztupinszki Z; Prosz A; Tisza V; Spisak S; Rusz O; Stormoen DR; Pappot H; Csabai I; Brunak S; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Jul; 27(13):3734-3743. PubMed ID: 33947694
[TBL] [Abstract][Full Text] [Related]
35. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
[TBL] [Abstract][Full Text] [Related]
36. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic
Batalini F; Madison RW; Sokol ES; Jin DX; Chen KT; Decker B; Pavlick DC; Frampton GM; Wulf GM; Garber JE; Oxnard G; Schrock AB; Tung NM
JCO Precis Oncol; 2023 Sep; 7():e2300091. PubMed ID: 37992259
[TBL] [Abstract][Full Text] [Related]
37. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract][Full Text] [Related]
38. Homologous recombination proficiency in ovarian and breast cancer patients.
Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
[TBL] [Abstract][Full Text] [Related]
39. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
40. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
